NCT07654374
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Not Yet Recruiting
PHASE3Ages 18–79InterventionalTreatmentGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
~1,100 participants
Updated 2026-06-22 on ClinicalTrials.gov
What's tested:aleniglipronPlacebo
At a glance
Recruiting sites
0 of 74 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change in body weight from Baseline
Measured over Baseline and week 76
Conditions
Where it's being run
74 sites across 30 statesFlorida8
California7
Texas7
Georgia5
Missouri5
North Carolina5
Arizona4
New York4
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Signed Informed Consent
Have a BMI ≥27.0 kg/m2 at Screening
Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening
Exclusion
Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.
Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.
Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
Self-reported change in body weight \>5 kg (11 pounds) within 3 months before Screening.
Have prior or planned surgical or non-surgical treatment for obesity.
What this trial measures
- Percent change in body weight from BaselineBaseline and week 76